 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- UF-KURE19 / Case Comprehensive Cancer Center
Development and Clinical Validation of an Ultra-Fast CAR-T Manufacturing Platform Enabling Production of CAR-T Cells in Less Than 1 Day (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6305;
UF-Kure19 cells expanded robustly in the patient and peaked around day 10 (23% of circulating CD3) with a strong skewing of CD4/CD8 cells (93% CD8+ T cells on day 10)...In vitro and animal data suggest this fast-manufacturing platform leads to potent CAR-T cells. Early human testing indicates CAR-T cells generated using this novel system have clinical activity against hematologic malignancies.
- | UF-KURE19 / Case Comprehensive Cancer Center
Trial completion date, Trial initiation date, Trial primary completion date: Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov) - May 12, 2023
P1, N=10, Recruiting, Sponsor: James Michael Martin
Early human testing indicates CAR-T cells generated using this novel system have clinical activity against hematologic malignancies. Trial completion date: Dec 2026 --> Dec 2024 | Initiation date: Oct 2023 --> Apr 2023 | Trial primary completion date: Jun 2026 --> Jun 2024
- | UF-KURE19 / Case Comprehensive Cancer Center
Enrollment open: Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov) - Nov 25, 2022
P1, N=10, Recruiting, Sponsor: James Michael Martin
Trial completion date: Dec 2026 --> Dec 2024 | Initiation date: Oct 2023 --> Apr 2023 | Trial primary completion date: Jun 2026 --> Jun 2024 Not yet recruiting --> Recruiting
- | UF-KURE19 / Case Comprehensive Cancer Center
New P1 trial: Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (clinicaltrials.gov) - May 31, 2022
P1, N=10, Not yet recruiting, Sponsor: James Michael Martin